source
- Hims sales dip as telehealth rivals intensify; Bristol partners with Chinese firm, other biotech updatesHims reported lower sales this quarter, attributing the shortfall to growing competition from other telehealth providers. Bristol announced a new partnership with Chinese drugmaker Hengrui Pharma…
- Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel PharmaceuticalsArvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…